首页 > 市场调查报告书 > 医疗设备

生技设备 3D列印

市场调查报告书

商品编码

1345380

全球 3D 生物打印市场 - 2023-2030

Global 3D Bioprinting Market - 2023-2030

出版日期: 2023年09月06日 | 出版商:

DataM Intelligence | 英文 195 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概况

全球 3D 生物打印市场将于 2022 年达到 20 亿美元，预计到 2030 年将达到 64 亿美元，2023-2030 年预测期间复合年增长率为 16.1%。

在被称为 3D 生物打印的增材製造方法中，活细胞和营养物质与有机和生物成分结合在一起，产生类似于天然人体组织的合成结构。组织工程、生物工程和材料科学的分支都可以从 3D 生物打印的各种生物应用中受益。此外，该技术越来越多地用于药物研究和审批。目前生物打印研究的重点是临床应用，包括3D打印皮肤和骨移植、植入物，甚至完整的3D打印器官。

此外，政府倡议和激励计划的日益采用、3D生物打印机在美容治疗和进步中的使用不断增加、3D生物打印在临床研究和药物筛选中的使用有助于减少动物测试等因素正在推动增长3D生物打印市场规模。由于美国和加拿大等国家技术进步的巨大进步，北美地区的市场需求不断增加。

市场动态

公司遵循的策略有助于推动市场增长

产品发布、产品批准、合作伙伴关係和收购等策略有助于推动市场增长。例如，2021 年3 月，领先的生物融合公司CELLINK 推出了BIO MDX 系列，这是最新一代的生物打印机，用于高通量生物製造和生物医学生产的精确3D 生物打印，包括创建生物相容性医疗设备。在世界上。

过去五年来，随着 3D 生物打印作为组织工程、细胞培养和再生医学领域研究人员的首选技术越来越受欢迎，生物製造技术对更好的自动化、精度和可重复性的需求越来越大。

此外，2022 年 11 月 22 日，一家名为 Avay Biosciences 的印度科技初创公司推出了一款国产 3D 打印机，据该公司称，该打印机可以製造人体组织。印度科学研究所安装了“Mito Plus”生物打印机的第一台原型机。复杂的生物 3D 打印机 Mito Plus 由 Avay 创建，该公司由印度理工学院马德拉斯分校的一位校友共同创立，并得到了 IISc 研究实验室对原型的反馈。因此，新产品推出的增加有助于市场扩张。

治疗技术的进步

近年来，3D生物打印的目标取得了显着进步，现在可以打印可以成功移植到人体的器官。儘管距离实现这一目标还有很长的路要走，但该技术仍在研究和开发中，其进步可能会带来新的、更好的治疗疾病的方法，包括脑癌、帕金森病、阿尔茨海默病和脊髓损伤等。

经过一些修改，普通 3D 打印技术可用于创建 3D 活细胞。根据 CAD 文件，打印机在连续的层中应用材料来创建形状。生物墨水是生物打印机使用的材料，而不是金属或聚合物。它们由藻酸盐或明胶等粘性物质製成，并含有活细胞。脚手架经常用于在细胞创建时支撑和保护细胞。由于最近取得的许多进展，3D 生物打印业务正在不断扩大。

例如，根据美国机械工程师协会的说法，新发明是一种便携式 3D 打印机，可以沉积生物材料皮肤片来覆盖大面积烧伤伤口。此外，生物材料还能加速癒合过程。该技术由多伦多森尼布鲁克医院和多伦多大学的研究人员开发，将生物墨水逐条烧伤伤口。间充质基质细胞（MSC）是一种可以根据其环境发育成多种细胞类型的干细胞，用于製造生物材料。因此，技术的发展有助于市场的扩张。

治疗费用高

儘管许多人认为使用这种先进技术可以让患者尽快进行器官移植，但手术费用昂贵。随着技术的进步，做任何事情的成本都会增加。生物打印器官所需材料的成本也增加了。

虽然生产活体组织的成本低至 1,000 美元，但大多数用于 3D 器官打印的生物打印机的成本可能高达 100,000 美元。器官打印成本高昂，因为需要花费大量时间进行所需的研究，并且需要高素质和经验丰富的工人来确保过程有效。因此，由于器官成本昂贵将限制市场增长。

Market Overview

Global 3D Bioprinting Market reached US$ 2.0 billion in 2022 and is expected to reach US$ 6.4 billion by 2030 growing with a CAGR of 16.1% during the forecast period 2023-2030.

In the additive manufacturing method known as 3D bioprinting, living cells and nutrients are joined with organic and biological components to produce synthetic structures that resemble natural human tissues. The branches of tissue engineering, bioengineering, and materials science can all benefit from 3D bioprinting for a variety of biological applications. Additionally, the technology is increasingly being used for drug research and approval. The present focus of bioprinting research is on clinical applications including 3D printed skin and bone grafts, implants, and even complete 3D printed organs.

Additionally, factors such as the rising adoption of government initiatives, and incentive programs, the rising use of 3D bioprinters in beauty treatments and advancements, the use of 3D bioprinting in clinical studies and drug screening which helps to reduce animal testing, are driving the growth of the 3D Bioprinting market size. Due to the massive rise in technological advancements in countries like the U.S. and Canada, the market is experincing an rise in demand from North American regions.

Market Dynamics

The Strategies Followed by the Companies Helps to Drive the Market Growth

The strategies like product launches, product approvals, partnerships and acquisitions helps to drive the market growth. For instance, in March 2021, the BIO MDX Series, the most recent generation of bioprinters created for high-throughput biofabrication and precise 3D bioprinting for biomedical production, including the creation of biocompatible medical equipment, has been introduced by CELLINK, the leading bioconvergence firm in the world.

There has been a larger need for better automation, precision, and repeatability across biofabrication techniques over the past five years as 3D bioprinting has grown in popularity as the technique of choice for researchers working in the fields of tissue engineering, cell culture, and regenerative medicine.

Additionally, on November 22, 2022, an Indian tech start-up called Avay Biosciences has unveiled a homegrown 3D printer that, according to the company, can manufacture human tissues. At the Indian Institute of Science, the 'Mito Plus' bioprinter's first prototype was installed. The sophisticated Bio 3D printer Mito Plus was created by Avay, which was co-founded by an IIT Madras alumnus, with feedback on the prototype from the research lab at IISc. Thus, an increase in new product launches contributes to market expansion.

Technological Advancements in the Treatment

The objective of 3D bioprinting has advanced significantly in recent years, and it is now possible to print organs that can be successfully transplanted into people. Even while that is still a long way off, the technique is still being researched and developed, and advancements could result in new and better therapies for ailments including brain cancer, Parkinson's disease, Alzheimer's disease, and spinal cord injury, among many others.

With a few modifications, normal 3D printing techniques are used to create living cells in 3D. In accordance with a CAD file, the printer applies material in successive layers to create a shape. Bioinks are the materials used by bioprinters instead of metals or polymers. These are made of viscous substances like alginate or gelatin and contain living cells. Scaffolding is frequently used to support and safeguard the cells while they are created. The 3D bioprinting business is expanding as a result of many recent advancements.

For instance, according to American Society of Mechnical Engineers, new invention is a portable 3D printer that deposits sheets of biomaterial skin to cover big burn wounds. Additionally, the biomaterial speeds up the healing process. The technology, developed by researchers at Sunnybrook Hospital and the University of Toronto in Toronto, applies bio ink to burn wounds strip by strip. The mesenchymal stroma cells (MSCs), stem cells that can develop into multiple cell types depending on their environment, are used to make the biomaterial. Thus, the growth of technology contributes to market expansion.

High cost of Treatment

Even though many people believe that using this advanced technology will allow patients to have an organ transplant as soon as possible, the operation is not affordable. The cost of having anything done increases as technology advances. The cost of the materials required for bioprinting organs has also increased.

While producing living tissues can cost as little as $1,000, the majority of bioprinters used for 3D organ printing can cost as much as $100,000. Organ printing is expensive due to the fact that it takes a lot of time to do the needed research and because it needs highly qualified and experienced workers to make sure the process is effective. Thus due to expensive cost of organs will restrict the market growth.

Segment Analysis

The global 3D bioprinting market is segmented based on component, technology, application, end user and region.

The Hospitals Accounted for Approximately 31.07% of the 3D Bioprinting Market Share

Using 3D bioprinting, surgeons may make patient-specific organ models. By enabling them to visualize the patient's particular anatomy and perform the procedure beforehand, these models can aid them in planning complicated surgeries. This may result in surgeries that are more successful and accurate. Surgeons can produce tissue constructions from a patient's own cells using 3D bioprinting. The use of these constructions as grafts or replacements can help in tissue regeneration. In order to help surgeons better prepare for operation, 3D printing also enables medical personnel to create reference models from MRI and CT scans, which is driving the segment's revenue growth.

Moreover, strategic collaborations between major market companies and hospitals for the implementation of 3D printing for healthcare purposes is driving revenue growth of this segment.For instance, in Feburary 2021, Anatomiz3D Medtech and the Apollo Hospitals have worked collaboratively to design and construct hospital 3D printing facilities in India that would allow surgeons to visualize and manufacture implants for challenging surgical cases. The medical and surgical staff at Apollo Hospitals will collaborate with a multidisciplinary team made up of engineers and 3D designers in the hospital's 3D printing facilities. Thus, those mentioned elements aid in accelerating segment expansion.

Geographical Penetration

North America Accounted for Approximately 44.9% of the Market Share in 2022

The 3D bioprinting market is expanding in this region due to the increasing use of 3D bioprinting in hospitals for its features. The outstanding medical education and training programs in North America produce a workforce that is ready for implementing innovative technologies, such 3D bioprinting, in hospitals and clinics. Moreover, rising investments from companies and governmental entities, in addition to technological advancements in healthcare infrastructure are some factors helps to accelerate region growth.

For instance, in June 2023, In order to improve 3D bioprinting, 3D BioFibR, a Canadian tissue engineering company, has launched two new collagen fiber products: CollaFibR and CollaFibR 3D scaffold. The innovative, exclusive dry-spinning process developed by 3D BioFibR, which can produce collagen fibers at industrial scales, is used to make these new off-the-shelf products. According to details, these new products will provide significant benefits for applications involving tissue engineering and tissue culture. Thus, all of the above factors contribute to the region's growth.

Competitive Landscape

The major global players in the 3D bioprinting market Organovo Holdings Inc, UPM Biomedicals, GE Healthcare, Regemat 3D, 3DSMAN, CELLINK, Aspect Biosystem, Formlabs, Avay Biosciences, Precise Bio and others.

COVID-19 Impact Analysis

A variety of chronic disorders have been caused by the worldwide pandemic, aiding in the unexpected expansion of the 3D bioprinting companies. Healthcare professionals, the community, and the government face new challenges with each COVID-19 wave in terms of minimizing its impact and aftereffects. The last multiple waves encountered a problem with the shortage of COVID-19 test kits.

This significant issue was addressed by numerous 3D bioprinting companies, and test kits were produced in huge quantities. According to reports, Formlabs, one of the American businesses, produced 100,000 nose swabs for COVID-19 testing per day. Recently, a great number of pharmaceutical firms, R&D centers, and healthcare professionals have united to battle this terrible global pandemic in every way available.

By Component

3D Bioprinters
Bioinks

By Technology

Extrusion-based bioprinting
Inkjet-based bioprinting
Pressure-assisted bioprinting
Laser-assisted bioprinting
Others

By Application

Medical

Tissue And Organ Generation

Medical Pills

Prosthetics And Implants

Others

Dental
Biosensors
Consumer/Personal Product Testing
Others

By End User

Hospitals
Research Organizations and Academic Institutes
Biopharmaceutical Companies

By Region

North America

U.S.

Canada

Mexico

Europe

Germany

France

Spain

Italy

Rest of Europe

South America

Brazil

Argentina

Rest of South America

Asia-Pacific

China

India

Japan

Australia

Rest of Asia-Pacific

Middle East and Africa

Key Developments

In Feburary 2023, an new strategy for surgical operations requiring the reconstruction of human tissues has been developed by 3D Systems as a component of its tissue regeneration program. After making great strides in the creation of advanced bioprinting solutions for 3D printed solid organs, the company launched this program.
In March 2023, LabSkin and Chanel produce 3D bioprinted skin with spots. In order to advance its understanding of skin pigment spots, a key cosmetic problem among aging populations, particularly in Asia,. The luxury brand has successfully employed 3D bioprinting technologies to generate reconstructed human skin on which a dark spot can form in collaboration with LabSkin Creations.
In June 2022, the first multi-material, multi-fluidic bioprinting printhead, according to Finland-based bioprinting company Brinter, has been introduced. The digital multifluidic printing tool head is now undergoing pilot testing with a small number of customers. It was created for use with the company's own 3D bioprinters and geared toward pharmaceutical firms and research universities.

Why Purchase the Report?

To visualize the global 3D bioprinting market segmentation based on component, technology, application, end user and region as well as understandkey commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous data points of 3D bioprinting market-level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping available as excel consisting of key products of all the major players.

The global 3D bioprinting market report would provide approximately 53 tables, 54 figures and 195 Pages.

Target Audience 2023

Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Component
3.2. Snippet by Technology
3.3. Snippet by Application
3.4. Snippet by End User
3.5. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. The strategies followed by the companies
  - 4.1.1.2. Technological advancements in the treatment
- 4.1.2. Restraints
  - 4.1.2.1. High cost of the treatment
- 4.1.3. Opportunity
  - 4.1.3.1. Increasing demand of organ transplantation
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's 5 Forces Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Unmet Needs
5.6. Epidemiology Stats
5.7. Pipeline Analysis
5.8. Patent Analysis
5.9. Technology Trend
5.10. Russia-Ukraine War Impact Analysis
5.11. SWOT Analysis

6. COVID-19 Analysis

6.1. Analysis of COVID-19
- 6.1.1. Scenario Before COVID-19
- 6.1.2. Scenario During COVID-19
- 6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion

7. By Component

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
- 7.1.2. Market Attractiveness Index, By Component
7.2. 3D Bioprinters *
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  - 7.2.2.1. Medical Beds
  - 7.2.2.2. Bathroom & Toilet Assist Devices
  - 7.2.2.3. Reading, Writing & Computing Aids
- 7.2.3. Bioinks

8. By Technology

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 8.1.2. Market Attractiveness Index, By Technology
8.2. Extrusion-based bioprinting *
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Inkjet-based bioprinting
8.4. Pressure-assisted bioprinting
8.5. Laser-assisted bioprinting
8.6. Others

9. By Application

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.1.2. Market Attractiveness Index, By Application
9.2. Medical *
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  - 9.2.2.1. Tissue And Organ Generation
  - 9.2.2.2. Medical Pills
  - 9.2.2.3. Prosthetics And Implants
  - 9.2.2.4. Others
9.3. Dental
9.4. Biosensors
9.5. Consumer/Personal Product Testing
9.6. Others

10. By End User

10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 10.1.2. Market Attractiveness Index, By End User
10.2. Hospitals *
- 10.2.1. Introduction
- 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Research Organizations and Academic Institutes
10.4. Biopharmaceutical Companies

11. By Region

11.1. Introduction
- 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 11.1.2. Market Attractiveness Index, By Region
11.2. North America
- 11.2.1. Introduction
- 11.2.2. Key Region-Specific Dynamics
- 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
- 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.2.7.1. U.S.
  - 11.2.7.2. Canada
  - 11.2.7.3. Mexico
11.3. Europe
- 11.3.1. Introduction
- 11.3.2. Key Region-Specific Dynamics
- 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
- 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.3.7.1. Germany
  - 11.3.7.2. U.K.
  - 11.3.7.3. France
  - 11.3.7.4. Spain
  - 11.3.7.5. Italy
  - 11.3.7.6. Rest of Europe
11.4. South America
- 11.4.1. Introduction
- 11.4.2. Key Region-Specific Dynamics
- 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
- 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.4.7.1. Brazil
  - 11.4.7.2. Argentina
  - 11.4.7.3. Rest of South America
11.5. Asia-Pacific
- 11.5.1. Introduction
- 11.5.2. Key Region-Specific Dynamics
- 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
- 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.5.7.1. China
  - 11.5.7.2. India
  - 11.5.7.3. Japan
  - 11.5.7.4. Australia
  - 11.5.7.5. Rest of Asia-Pacific
11.6. Middle East and Africa
- 11.6.1. Introduction
- 11.6.2. Key Region-Specific Dynamics
- 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
- 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

12. Competitive Landscape

12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis

13. Company Profiles

13.1. Organovo Holdings Inc*
- 13.1.1. Company Overview
- 13.1.2. ProductPortfolio and Description
- 13.1.3. Financial Overview
- 13.1.4. Key Developments
13.2. UPM Biomedicals
13.3. GE Healthcare
13.4. Regemat 3D
13.5. 3DSMAN
13.6. CELLINK
13.7. Aspect Biosystem
13.8. Formlabs
13.9. Avay Biosciences
13.10. Precise Bio.

LIST NOT EXHAUSTIVE